High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). (2018)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.12688/wellcomeopenres.14691.1

PubMed Identifier: 30175245

Publication URI: http://europepmc.org/abstract/MED/30175245

Type: Journal Article/Review

Volume: 3

Parent Publication: Wellcome open research

ISSN: 2398-502X